Andrew Craig Miller - 10 Jun 2021 Form 4 Insider Report for Karuna Therapeutics, Inc.

Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
10 Jun 2021
Net transactions value
-$3,546,153
Form type
4
Filing time
14 Jun 2021, 21:13:19 UTC
Previous filing
12 May 2021
Next filing
18 Aug 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRTX Common Stock Options Exercise $122,664 +13,333 +29% $9.20* 58,833 10 Jun 2021 Direct
transaction KRTX Common Stock Sale $1,649,025 -13,333 -23% $123.68 45,500 10 Jun 2021 Direct F1
transaction KRTX Common Stock Options Exercise $76,664 +8,333 +18% $9.20* 53,833 11 Jun 2021 Direct
transaction KRTX Common Stock Sale $1,077,707 -8,333 -15% $129.33 45,500 11 Jun 2021 Direct F1
transaction KRTX Common Stock Options Exercise $76,673 +8,334 +18% $9.20* 53,834 14 Jun 2021 Direct
transaction KRTX Common Stock Sale $1,095,421 -8,334 -15% $131.44 45,500 14 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Options Exercise $0 -13,333 -4.4% $0.000000 287,159 10 Jun 2021 Common Stock 13,333 $9.20 Direct F2
transaction KRTX Option (right to buy) Options Exercise $0 -8,333 -2.9% $0.000000 278,826 11 Jun 2021 Common Stock 8,333 $9.20 Direct F2
transaction KRTX Option (right to buy) Options Exercise $0 -8,334 -3% $0.000000 270,492 14 Jun 2021 Common Stock 8,334 $9.20 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 This option vests and becomes exercisable in thirty equal monthly installments beginning on March 21, 2019.